Peeling Back The Layers: Exploring Sutro Biopharma Through Analyst Insights
Portfolio Pulse from Benzinga Insights
Sutro Biopharma (NASDAQ:STRO) has been analyzed by five analysts, showing a range of opinions from bullish to bearish. The average 12-month price target is $13.6, down 4.23% from the previous $14.20. Analysts have maintained or lowered their ratings, with price targets ranging from $12.00 to $17.00. Sutro Biopharma is a clinical-stage company focused on developing biopharmaceutical products, with significant revenue growth but challenges in ROE.
October 11, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Sutro Biopharma has received mixed analyst ratings, with a current average price target of $13.6, a decrease from $14.20. The company shows strong revenue growth but faces challenges in return on equity.
The mixed analyst ratings and the decrease in the average price target suggest a neutral short-term impact on the stock price. While the company shows strong revenue growth, the challenges in ROE and the decrease in price target indicate potential concerns for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100